唐珏;姚志荣;
TANG Jue;YAO Zhirong;Department of Dermatology, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine;

• 1:上海交通大学医学院附属新华医院皮肤科

摘要(Abstract)：

特应性皮炎(atopic dermatitis, AD)是一种慢性复发性炎症性皮肤病，慢性瘙痒是其特征性症状之一。AD瘙痒的发生机制复杂，目前认为与皮肤屏障功能障碍、免疫调节异常及外界环境因素相关；瘙痒-搔抓恶性循环可加重皮肤屏障的破坏、促进皮肤炎症反应及神经失调过程，是AD瘙痒不易控制的原因之一。目前控制AD瘙痒的药物包括外用药物和系统药物，AD瘙痒机制的研究为其治疗提供了新靶点，如IL-4、IL-13、IL-31、JAK、IL-33等。本文就AD瘙痒机制及相关治疗研究进展进行综述。
Atopic dermatitis(AD) is a chronic recurrent inflammatory skin disease characterized by intense pruritus. A satisfactory understanding of itch in AD has been proved difficult to reach and the relapsing itch is believed to be primarily a result of dysfunction of the skin barrier, dysregulation of the immune system and multiple environmental factors. Itch-scratch cycle exacerbates skin lesions, promotes inflammation and neurological disorders, and triggers the desire to continue scratching. The current methods of treatment for controlling AD pruritus symptoms include topical and systemic drugs. The exploration on the mechanisms of atopic pruritus has provided novel therapeutic targets, such as IL-4,IL-13,IL-31,JAK,IL-33. The new advances in the mechanism and treatment of itch in AD were systemically reviewed.

关键词(KeyWords)： 特应性皮炎;瘙痒;皮肤屏障;炎症;靶点
atopic dermatitis;pruritus;skin barrier;inflammation;target

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81874252)~~

作者(Authors): 唐珏;姚志荣;
TANG Jue;YAO Zhirong;Department of Dermatology, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine;

参考文献(References)：

• [1] Weidinger S,Beck LA,Bieber T,et al.Atopic dermatitis[J].Nat Rev Dis Primers,2018,4:1.
• [2] Shaw TE,Currie GP,Koudelka CW,et al .Eczema pre-valence in the United States:data from the 2003 National Survey of Children's Health[J].J Invest Dermatol,2011,131:67- 73.
• [3] Albrecht M,Dittrich AM.Expression and function of histamine and its receptors in atopic dermatitis[J].Mol Cell Pediatr,2015,2:16.
• [4] Bataille A,Leschiera R,L'Hérondelle K,et al.In Vitro Differentiation of Human Skin-Derived Cells into Functional Sensory Neurons-Like[J].Cells,2020,9:1000.
• [5] Cevikbas F,Wang X,Akiyama T,et al.A sensory neuron-expressed IL- 31 receptor mediates T helper cell-dependent itch:Involvement of TRPV1 and TRPA1[J].J Allergy Clin Immunol,2014,133:448- 460.
• [6] Tsakok T,Woolf R,Smith CH,et al.Atopic dermatitis:the skin barrier and beyond[J].Br J Dermatol,2019,180:464- 474.
• [7] Oetjen LK,Mack MR,Feng J,et al.Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch[J].Cell,2017,171:217- 228.e13.
• [8] Wilson SR,Thé L,Batia LM,et al.The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch[J].Cell,2013,155:285- 295.
• [9] St?nder S,Steinhoff M.Pathophysiology of pruritus in atopic dermatitis:an overview[J].Exp Dermatol,2002,11:12- 24.
• [10] Wang F,Trier AM,Li F,et al.A basophil-neuronal axis promotes itch[J].Cell,2021,184:422- 440.e17.
• [11] Petersen LJ,Church MK,Skov PS.Platelet-activating factor induces histamine release from human skin mast cells in vivo,which is reduced by local nerve blockade[J].J Allergy Clin Immunol,1997,99:640- 647.
• [12] Tsagareli MG,Nozadze I,Tsiklauri N,et al.Thermal Hyperalgesia and Mechanical Allodynia Elicited by Histamine and Non-histaminergic Itch Mediators:Respective Involvement of TRPV1 and TRPA1[J].Neuroscience,2020,449:35- 45.
• [13] McNeil BD,Pundir P,Meeker S,et al.Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J].Nature,2015,519:237- 241.
• [14] Chandran V,Coppola G,Nawabi H,et al.A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program[J].Neuron,2016,89:956- 970.
• [15] Zhang H,Guo Y,Wang W,et al.Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis[J].Allergy,2011,66:420- 427.
• [16] Howell MD,Parker ML,Mustelin T,et al.Past,present,and future for biologic intervention in atopic dermatitis[J].Allergy,2015,70:887- 896.
• [17] Mack MR,Kim BS.The Itch-Scratch Cycle:A Neuroim-mune Perspective[J].Trends Immunol,2018,39:980- 991.
• [18] Uche LE,Gooris GS,Bouwstra JA,et al.Barrier Capability of Skin Lipid Models:Effect of Ceramides and Free Fatty Acid Composition[J].Langmuir,2019,35:15376- 15388.
• [19] Imai Y,Yasuda K,Nagai M,et al.IL- 33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils[J].J Invest Dermatol,2019,139:2185- 2194.e3.
• [20] Smith L,Gatault S,Casals-Diaz L,et al.House dust mite-treated PAR2 over-expressor mouse:A novel model of atopic dermatitis[J].Exp Dermatol,2019,28:1298- 1308.
• [21] Skabytska Y,Kaesler S,Volz T,et al.The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments[J].Semin Immunopathol,2016,38:29- 43.
• [22] Gittler JK,Shemer A,Suárez-Fariňas M,et al.Progres-sive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis[J].J Allergy Clin Immunol,2012,130:1344- 1354.
• [23] Akdis CA,Arkwright PD,Brüggen MC,et al.Type 2 immunity in the skin and lungs[J].Allergy,2020,75:1582- 1605.
• [24] Tsoi LC,Rodriguez E,St?lzl D,et al.Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses[J].J Allergy Clin Immunol,2020,145:1406- 1415.
• [25] Imamachi N,Park GH,Lee H,et al.TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms[J].Proc Natl Acad Sci USA,2009,106:11330- 11335.
• [26] Wang F,Trier AM,Li F,et al.A basophil-neuronal axis promotes itch[J].Cell,2021,184:422- 440.e17.
• [27] Song S,Lee K,Lee YM,et al.Acute health effects of urban fine and ultrafine particles on children with atopic dermatitis[J].Environ Res,2011,111:394- 399.
• [28] 中国医师协会皮肤科医师分会过敏性疾病专业委员会，中华医学会皮肤性病学分会特应性皮炎研究中心，中国医疗保健国际交流促进会皮肤科分会.特应性皮炎瘙痒管理专家共识[J].中华皮肤科杂志，2021,54:391- 396.
• [29] Oyoshi MK,Larson RP,Ziegler SF,et al.Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression[J].J Allergy Clin Immunol,2010,126:976- 984.e9845.
• [30] Howell MD,Novak N,Bieber T,et al.Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis[J].J Invest Dermatol,2005,125:738- 745.
• [31] Hon KL,Tsang YC,Pong NH,et al.Patient acceptabi-lity,efficacy,and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema[J].Hong Kong Med J,2015,21:417- 425.
• [32] Seo SR,Lee SG,Lee HJ,et al.Disrupted Skin Barrier is Associated with Burning Sensation after Topical Tacrolimus Application in Atopic Dermatitis[J].Acta Derm Venereol,2017,97:957- 958.
• [33] Richardson GS,Roehrs TA,Rosenthal L,et al.Tolerance to daytime sedative effects of H1 antihistamines[J].J Clin Psychopharmacol,2002,22:511- 515.
• [34] Zhang X,Wu Z,Hayashi Y,et al.Peripheral role of cathepsin S in Th1 cell-dependent transition of nerve injury-induced acute pain to a chronic pain state[J].J Neurosci,2014,34:3013- 3022.
• [35] Lee YW,Won CH,Jung K,et al.Efficacy and safety of PAC- 14028 cream-a novel,topical,nonsteroidal,selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis:a phase Ⅱb randomized trial[J].Br J Dermatol,2019,180:1030- 1038.
• [36] Kuznik A,Bégo-Le-Bagousse G,Eckert L,et al.Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults[J].Dermatol Ther (Heidelb),2017,7:493- 505.
• [37] Blauvelt A,de Bruin-Weller M,Gooderham M,et al.Long-term management of moderate-to-severe atopic derma-titis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS):a 1-year,randomised,double-blinded,placebo-controlled,phase 3 trial[J].Lancet,2017,389:2287- 2303.
• [38] Simpson EL,Paller AS,Siegfried EC,et al.Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis:A Phase 3 Randomized Clinical Trial[J].JAMA Dermatol,2020,156:44- 56.
• [39] 中华医学会皮肤性病学分会免疫学组，特应性皮炎协作研究中心.中国特应性皮炎诊疗指南(2020版)[J].中华皮肤科杂志，2020,53:81- 88.
• [40] Ruzicka T,Mihara R.Anti-Interleukin- 31 Receptor A Antibody for Atopic Dermatitis[J].N Engl J Med,2017,376:2092- 2093.
• [41] Bao L,Zhang H,Chan LS.The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis[J].JAKSTAT,2013,2:e24137.
• [42] Guttman-Yassky E,Silverberg JI,Nemoto O,et al.Baricitinib in adult patients with moderate-to-severe atopic dermatitis:A phase 2 parallel,double-blinded,randomized placebo-controlled multiple-dose study[J].J Am Acad Dermatol,2019,80:913- 921.e9.
• [43] Simpson EL,Sinclair R,Forman S,et al.Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1):a multicen-tre,double-blind,randomised,placebo-controlled,phase 3 trial[J].Lancet,2020,396:255- 266.
• [44] Guttman-Yassky E,Tha?i D,Pangan AL,et al.Upadacitinib in adults with moderate to severe atopic dermatitis:16-week results from a randomized,placebo-controlled trial[J].J Allergy Clin Immunol,2020,145:877- 884.
• [45] Papp K,Szepietowski JC,Kircik L,et al.Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis:Results from 2 phase 3,randomized,double-blind studies[J].J Am Acad Dermatol,2021,85:863- 872.
• [46] Ciaravino V,Coronado D,Lanphear C,et al.2-Year animal carcinogenicity results for crisaborole,a novel phosphodiesterase 4 inhibitor for atopic dermatitis[J].J Dermatol Sci,2017,87:116- 122.
• [47] Chen YL,Gutowska-Owsiak D,Hardman CS,et al.Proof-of-concept clinical trial of etokimab shows a key role for IL- 33 in atopic dermatitis pathogenesis[J].Sci Transl Med,2019,11:eaax2945.
• [48] 黄世杰.依托吉单抗治疗中重度特应性皮炎未能达到主终点[J].国际药学研究杂志，2020,47:402.
• [49] Simpson EL,Parnes JR,She D,et al.Tezepelumab,an anti-thymic stromal lymphopoietin monoclonal antibody,in the treatment of moderate to severe atopic dermatitis:A randomized phase 2a clinical trial[J].J Am Acad Dermatol,2019,80:1013- 1021.